- Trials with a EudraCT protocol (42)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
42 result(s) found for: Stabilizers.
Displaying page 1 of 3.
EudraCT Number: 2013-002055-15 | Sponsor Protocol Number: J81J1100168007 | Start Date*: 2014-01-28 |
Sponsor Name:UNIVERSITY OF SASSARI | ||
Full Title: RANDOMIZED, CONTROLLED, MULTI-CENTER, INTERNATIONAL CLINICAL STUDY ON THE MOOD-STABILIZING EFFECTS OF MEMANTINE AS AN AUGMENTING AGENT vs. LAMOTRIGINE FOR ONGOING TREATMENT IN BIPOLAR-I DISORDER P... | ||
Medical condition: BIPOLAR I MOOD DISORDERS | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-000394-60 | Sponsor Protocol Number: ACR16C007 | Start Date*: 2004-06-30 |
Sponsor Name:A. Carlsson Research AB | ||
Full Title: A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease | ||
Medical condition: ACR16 belongs to a new class of CNS active agents called dopaminergic stabilizers. Dopaminergic stabilizers are compounds that can both enhance and counteract dopamine dependent functions in the CN... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-023623-26 | Sponsor Protocol Number: C10953/3073 | Start Date*: 2011-07-14 | |||||||||||
Sponsor Name:Cephalon, Inc. | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depressio... | |||||||||||||
Medical condition: Major Depression Associated With Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) FI (Completed) DE (Completed) IT (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005345-19 | Sponsor Protocol Number: R076477BIM3003 | Start Date*: 2006-05-25 |
Sponsor Name:Janssen-Cilag International N.V. | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone as Adjunctive Therapy to Mood S... | ||
Medical condition: Bipolar I Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: EE (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017581-22 | Sponsor Protocol Number: 20091003 | Start Date*: 2011-01-04 |
Sponsor Name:Department of Psychiatry and Psychotherapy, Charity University Medicine | ||
Full Title: Cognitive impairment in bipolar disorder treated with aripiprazole | ||
Medical condition: Bipolar disorder is among the most severely debilitating diseases. Patients with bipolar disorder generally experience high rates of relapse, a chronic recurrent course, lingering residual symptoms... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016648-38 | Sponsor Protocol Number: C10953/3074 | Start Date*: 2010-08-06 |
Sponsor Name:Cephalon, Inc. | ||
Full Title: A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With ... | ||
Medical condition: Major Depression Associated With Bipolar I Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) BG (Prematurely Ended) ES (Completed) DE (Prematurely Ended) FI (Completed) SK (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-004249-16 | Sponsor Protocol Number: F02207GE204 | Start Date*: 2005-02-02 |
Sponsor Name:PIERRE FABRE MEDICAMENT | ||
Full Title: THE EFFECT OF MILNACIPRAN 100MG BID ON SENSITIVITY TO STIMULUS-EVOKED PAIN IN PATIENTS WITH FIBROMYALGIA: A FMRI NEUROIMAGING STUDY | ||
Medical condition: Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, widespread tenderness and fatigue. The disorder is well defined in the USA, where the current diagnosis of FMS i... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) SE (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001890-15 | Sponsor Protocol Number: SD-809-C-18 | Start Date*: 2014-11-12 |
Sponsor Name:Auspex Pharmaceuticals, Inc. | ||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA | ||
Medical condition: Tardive Dyskinesia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) PL (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004790-31 | Sponsor Protocol Number: 55308942BIP2001 | Start Date*: 2022-05-31 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression | |||||||||||||
Medical condition: Bipolar Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003002-12 | Sponsor Protocol Number: CMIJ821X2201 | Start Date*: 2019-04-08 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: A multi-center, randomized, subject and investigator-blinded, placebo-controlled, active comparator, parallel-group proof of concept study to evaluate the efficacy, safety, tolerability, and pharma... | |||||||||||||
Medical condition: Treatment Resistant Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001685-35 | Sponsor Protocol Number: ADT-2022-003 | Start Date*: 2022-12-27 | |||||||||||
Sponsor Name:Adeptio Pharmaceuticals Limited | |||||||||||||
Full Title: Randomized, double-blind, placebo controlled clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia. | |||||||||||||
Medical condition: Tardive dyskinesia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003137-40 | Sponsor Protocol Number: F02207GE302 | Start Date*: 2015-09-28 |
Sponsor Name:Pierre Fabre Medicament | ||
Full Title: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome. | ||
Medical condition: Fibromyalgia, also known as FMS, is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population Fibromyalgia is associated with a reduced threshold for pain, generally i... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) FI (Completed) SE (Completed) ES (Completed) PT (Completed) DE (Completed) GB (Completed) CZ (Completed) IT (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002676-10 | Sponsor Protocol Number: 31-07-247 | Start Date*: 2008-12-02 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mai... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) EE (Completed) HU (Completed) AT (Completed) FR (Completed) BG (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016667-11 | Sponsor Protocol Number: C10953/3071 | Start Date*: 2010-04-29 |
Sponsor Name:Cephalon, Inc. | ||
Full Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major D... | ||
Medical condition: Major Depression Associated With Bipolar I Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) BG (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016634-27 | Sponsor Protocol Number: C10953/3072 | Start Date*: 2010-06-03 |
Sponsor Name:Cephalon, Inc. | ||
Full Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major D... | ||
Medical condition: Major Depression Associated With Bipolar I Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) BG (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-012446-23 | Sponsor Protocol Number: 192371-016 | Start Date*: 2009-10-30 | |||||||||||
Sponsor Name:Allergan Ltd | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Masked, Parallel-Group Study Evaluating the Efficacy and Safety of Cyclosporine Ophthalmic Solution 0.010% Compared with its Vehicle Administered QID for 3 months ... | |||||||||||||
Medical condition: Atopic Keratoconjunctivitis is a bilateral, inflammatory external ocular disease. A serious disease driven by chronic inflammation of the cornea, conjunctiva and lower lid. AKC is commonly presen... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) FR (Completed) CZ (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004768-22 | Sponsor Protocol Number: C-05-30 | Start Date*: 2006-06-12 | |||||||||||
Sponsor Name:ALCON ITALIA | |||||||||||||
Full Title: Clinical study of the mast-cell stabilizing effects of the Olopatadine using the Conjunctival Allergen Challeenge model | |||||||||||||
Medical condition: subjects with a clinical history of seasonal allergic conjunctivitis, but asymptomatic and free of any topical or systemic medication at baseline | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011253-40 | Sponsor Protocol Number: PQ2 | Start Date*: 2009-04-23 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: Paroxetine or Quetiapine in Addition to Mood Stabilizers in Bipolar Depression | |||||||||||||
Medical condition: Major Depressive Episode in Bipolar Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002213-19 | Sponsor Protocol Number: ELICE-BD-O1 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:University of British Columbia | |||||||||||||
Full Title: A 6-Week Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Pa... | |||||||||||||
Medical condition: Euthymic Bipolar disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005293-22 | Sponsor Protocol Number: D589GC00003 | Start Date*: 2014-08-06 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 ug, 2 Actuations Twice Daily, and Symbicort pMDI 80... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: SK (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
